HF
STLN

HRT Financial’s Starling Oncology STLN Stock Holding History

HRT Financial’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,658
Closed -$18K – 3521
2025
Q1 		$18K Buy
+16,658
New +$12.9K ﹤0.01% 2313

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

HRT Financial's STLN Position: Q2 2025 in Review

HRT Financial sold out of Starling Oncology (STLN) in Q2 2025, closing a stake of 16,658 shares — an estimated $18K sold.

HRT Financial first reported a position in STLN in Q1 2025 and held it in 1 quarter. The position peaked at $18K in Q1 2025. 79 funds tracked by Wall St. Rank hold STLN as of Q2 2025.

  • HRT Financial reported no remaining Starling Oncology position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 16,658 Starling Oncology shares in Q2 2025, an estimated $18K.
  • HRT Financial first reported a position in Starling Oncology in Q1 2025 and held it in 1 quarter.
  • HRT Financial's Starling Oncology position peaked at $18K in Q1 2025.
  • 79 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.